

General information about company	
Scrip code*	532041
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE597C01021
Name of company	HINDUSTAN BIO SCIENCES LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	31-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	16-10-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	TRANDING OF PHARMACUTICALS
Start date and time of board meeting	31-10-2025 14:00
End date and time of board meeting	31-10-2025 15:45
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	03-05-2023
Indicate Company website link for updated RPT policy of the Company	https://www.hindustanbiosciences.in/Investor/Policies/Final%20Policy%20on%20RPT.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	

Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	The company is not committed any default. No debt securities issued
--	----	---

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	0	32.19
	Other income	0.86	2.17
	Total income	0.86	34.36
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	21.19
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	4.96	9.36
(e)	Finance costs	0.01	0.06
(f)	Depreciation, depletion and amortisation expense	0.39	0.39
(g)	Other Expenses		
1	Other Expenses	1.35	7.67
2	Selling Expenses	0	0.15
	Total other expenses	1.35	7.82
	Total expenses	6.71	38.82
3	Total profit before exceptional items and tax	-5.85	-4.46
4	Exceptional items	0	0
5	Total profit before tax	-5.85	-4.46
6	Tax expense		
7	Current tax	0	0
8	Deferred tax	0	0
9	Total tax expenses	0	0
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-5.85	-4.46
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-5.85	-4.46
17	Other comprehensive income net of taxes	0	0
18	Total Comprehensive Income for the period	-5.85	-4.46
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		

21	Details of equity share capital		
	Paid-up equity share capital	205.02	205.02
	Face value of equity share capital	2	2
22	Reserves excluding revaluation reserve		
23	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	-0.06	-0.04
	Diluted earnings (loss) per share from continuing operations	-0.06	-0.04
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	-0.06	-0.04
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.06	-0.04
24	Debt equity ratio	0	0
			Textual Information(1)
25	Debt service coverage ratio	0	0
			Textual Information(2)
26	Interest service coverage ratio	0	0
			Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)	

Statement of Asset and Liabilities		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	43.97
	Capital work-in-progress	
	Investment property	
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	0.99
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	
	Total non-current financial assets	0.99
	Deferred tax assets (net)	0
	Other non-current assets	239.97
	Total non-current assets	284.93
2	Current assets	
	Inventories	0
	Current financial asset	
	Current investments	0
	Trade receivables, current	5.3
	Cash and cash equivalents	0
	Bank balance other than cash and cash equivalents	1.63
	Loans, current	0
	Other current financial assets	
	Total current financial assets	6.93
	Current tax assets (net)	
	Other current assets	58.02
	Total current assets	64.95
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	349.88
	Total current assets	64.95
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	349.88
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	205.02
	Other equity	-118.98
	Total equity attributable to owners of parent	86.04

	Non controlling interest	
	Total equity	86.04
2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	261.61
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
	Total non-current financial liabilities	261.61
	Provisions, non-current	0
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	261.61
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	0
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0.28
	Total Trade payable	0.28
	Other current financial liabilities	
	Total current financial liabilities	0.28
	Other current liabilities	
	Provisions, current	1.95
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	2.23
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	263.84
	Total equity and liabilities	349.88
	Disclosure of notes on assets and liabilities	Textual Information(1)

Other Comprehensive Income			
	Date of start of reporting period	01-07-2025	01-04-2025
	Date of end of reporting period	30-09-2025	30-09-2025
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income		

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-4.46
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	0
	Adjustments for decrease (increase) in trade receivables, current	38.9
	Adjustments for decrease (increase) in trade receivables, non-current	-1
	Adjustments for decrease (increase) in other current assets	-3.62
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	0.21
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	0.39
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0.66
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	35.54
	Net cash flows from (used in) operations	31.08
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	31.08
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0

	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	-0.11
	Purchase of property, plant and equipment	0
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0.15
	Purchase of other long-term assets	41.69
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	-41.65
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	11.1
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	11.1
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	0.53
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	0.53

	Cash and cash equivalents cash flow statement at beginning of period	1.09
	Cash and cash equivalents cash flow statement at end of period	1.62

Format for Disclosure of Related Party Transactions (applicable only if)

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary					
1	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	J V R Mohan Raju	ABSPJ3771C	MD	Remuneration		3	Approved and no Remarks by Audit Committee	3
2	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	J V R Mohan Raju	ABSPJ3771C	MD/PRONOTER	Any other transaction	LOAN TAKEN	61.1	Approved and no Remarks by Audit Committee	61.1
3	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	J V R Mohan Raju	ABSPJ3771C	MD/PRONOTER	Any other transaction	LOAN REPAID	44.3	Approved and no Remarks by Audit Committee	44.3
4	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	SUPER SOLUTIONS (I) PVT. LTD	AACCS8219E	PROMOTER	Any other transaction	LOAN TAKEN	0	Approved and no Remarks by Audit Committee	0
5	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	SUPER SOLUTIONS (I) PVT. LTD	AACCS8219E	PROMOTER	Any other transaction	LOAN REPAID	3.5	Approved and no Remarks by Audit Committee	3.5
6	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	J UMA	AEQPJ1587B	PROMOTER	Any other transaction	LOAN TAKEN	0	Approved and no Remarks by Audit Committee	0
7	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	J UMA	AEQPJ1587B	PROMOTER	Any other transaction	LOAN REPAID	3.5	Approved and no Remarks by Audit Committee	3.5
8	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	DEVANSH DANGE	HGBPD5347F	COMPANY SECRETARY/COMPLIANCE OFFICER	Remuneration		0.98	Approved and no Remarks by Audit Committee	0.98
9	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	SHAIENDRA VYAS	BQDPV3086K	COMPANY SECRETARY/COMPLIANCE OFFICER	Remuneration		0.6	Approved and no Remarks by Audit Committee	0.6
10	HINDUSTAN BIO SCIENCES LIMITED	AABCG3236A	NIPUNA SHELTERS PRIVATE LIMITED	AABCR8865L	COMMON DIRECTOR	Any other transaction	LOAN REPAID	1.7	Approved and no Remarks by Audit Committee	1.7
Total value of transaction during the reporting period										

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Unaudited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	VASG & ASSOCIATES	Yes	30-04-2027

